ArticleNano research2016
NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.
Article in Nano research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation.Cell biology and toxicology · 2025Article
- NGR-modified nanovesicles target ALKBH5 to inhibit ovarian cancer growth and metastasis.Theranostics · 2025Article
- Polypeptides-Based Nanocarriers in Tumor Therapy.Pharmaceutics · 2024Review
- A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins.Cellular and molecular life sciences : CMLS · 2024Article
- Extracellular vesicle-derived silk fibroin nanoparticles loaded with MFGE8 accelerate skin ulcer healing by targeting the vascular endothelial cells.Journal of nanobiotechnology · 2023Article
- Advances in engineering and delivery strategies for cytokine immunotherapy.Expert opinion on drug delivery · 2023Article
- Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.Pharmaceutics · 2022Review
- Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.Advanced healthcare materials · 2021Review
- Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold.Journal of nanobiotechnology · 2021Article
- Delivery of cancer therapies by synthetic and bio-inspired nanovectors.Molecular cancer · 2021Review
- Clinical Application of Cytokines in Cancer Immunotherapy.Drug design, development and therapy · 2021Review
- Nanotechnology in the Treatment of Diabetic Complications: A Comprehensive Narrative Review.Journal of diabetes research · 2021Review
- Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.Nanomaterials (Basel, Switzerland) · 2020Review
- Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.Cancers · 2019Review
- Current applications and future prospects of nanotechnology in cancer immunotherapy.Cancer biology & medicine · 2019Article
- Rational design of a super-contrast NIR-II fluorophore affords high-performance NIR-II molecular imaging guided microsurgery.Chemical science · 2019Article
- Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.Theranostics · 2019Review
- Phosphate-Catalyzed Succinimide Formation from an NGR-Containing Cyclic Peptide: A Novel Mechanism for Deammoniation of the Tetrahedral Intermediate.Molecules (Basel, Switzerland) · 2018Article
- Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells.Journal of cancer research and clinical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Colloidal gold (Au), a well-tolerated nanomaterial, is currently exploited for several applications in nanomedicine. We show that gold nanoparticles tagged with a novel tumor-homing peptide containing Asn-Gly-Arg (NGR), a ligand of CD13 expressed by the tumor neovasculature, can be exploited as carriers for cytokine delivery to tumors. Biochemical and functional studies showed that the NGR molecular scaffold/linker used for gold functionalization is critical for CD13 recognition. Using fibrosarcoma-bearing mice, NGR-tagged nanodrugs could deliver extremely low, yet pharmacologically active doses of tumor necrosis factor (TNF), an anticancer cytokine, to tumors with no evidence of toxicity. Mechanistic studies confirmed that CD13 targeting was a primary mechanism of drug delivery and excluded a major role of integrin targeting consequent to NGR deamidation, a degradation reaction that generates the isoAsp-Gly-Arg (isoDGR) integrin ligand. NGR-tagged gold nanoparticles can be used, in principle, as a novel platform for single- or multi-cytokine delivery to tumor endothelial cells for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.